Health Innovation
5 Dutch Health Startups Bringing New Tools Into Clinical Care
DealBio tracks early-stage health startups across Europe and North America. These 5 Dutch startups are building around clinical work that already happens every day: monitoring patients, guiding surgery, protecting kidney function, managing nerves and supporting neonatal care.
- Netherlands
- Medtech
- Clinical Workflow
- Diagnostics
- Therapeutics
DealBio tracks early-stage health startups across Europe and North America. These 5 Dutch startups are building around clinical work that already happens every day: monitoring patients, guiding surgery, protecting kidney function, managing nerves and supporting neonatal care.
The stronger editorial pattern is workflow pressure. Hospitals and specialist teams do not need more standalone tools unless those tools remove friction from a specific step. Flowsure targets manual urine-output recording, Exolumen supports surgical navigation, and I See U Baby Care tries to make monitoring less disruptive in neonatal settings.
AVIGI Therapeutics and Atraxon Biotech broaden the article beyond hospital workflow software, but they keep the same practical focus: intervene at a defined point in disease or surgical care. Together, the group is useful because the adoption question is visible from the start — where does this fit, who uses it, and what burden does it remove?
At a Glance
- FlowsureNetherlands2025Automated urine-output monitoring
- ExolumenNetherlands2024Projection guidance for reconstructive surgery
- AVIGI TherapeuticsNetherlands2024Kidney-protective enzyme inhibition
- Atraxon BiotechNetherlands2024Surgical nerve-management implants
- I See U Baby CareNetherlands2024Non-contact neonatal sleep monitoring
01
Flowsure
Developing automated urine-output monitoring for hospital wards.
- Country
Netherlands- Founded
- 2025
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why Flowsure stands out
Flowsure completed a 75-participant urine-monitoring study and reported 2.3% median absolute volume error against a reference collection container in a separate analysed patient set.
A joint project supported through Health~Holland has a €1.5 million total budget to develop urine-data alerts with Amsterdam UMC.
What Flowsure is building
Flowsure’s monitor weighs a standard urine collection bag and converts changes in weight into output measurements for patients who already have a urinary catheter.
The reusable device sends measurements over Wi-Fi to the hospital record, reducing repeated manual entry and creating a more complete time series.
02
Exolumen
Developing surgical projectors that overlay anatomical data directly onto patients.
- Country
- Netherlands
- Founded
- 2024
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why Exolumen stands out
A 2019 randomized trial in 60 breast-reconstruction patients found that the predecessor Anatomy Projector reduced flap-harvest time by 19 minutes versus Doppler ultrasound guidance.
The predecessor was used in more than 400 surgeries at Radboudumc before Exolumen was incorporated.
What Exolumen is building
Exolumen projects anatomical information directly onto the patient, giving the surgical team a shared view without individual headsets.
Its platform maps blood-vessel locations from preoperative CT scans and can add thermal-imaging information to support tissue-transfer reconstruction.
Developing drugs to protect kidney function by blocking a tissue-damaging enzyme.
- Country
- Netherlands
- Founded
- 2024
- Sector
- Biotech
- Funding stage
- Seed or earlier
- Founders
- Vincent Lit
- Arian Khoshchin
- Hermen Overkleeft
- Gijs Ruijgrok
Why AVIGI Therapeutics stands out
AVIGI Therapeutics licensed inhibitor technology from Leiden University and secured a €350,000 convertible loan from UNIIQ in 2025.
Co-founders Vincent Lit and Hermen Overkleeft are named among the inventors on a published US patent application linked to the inhibitor technology.
What AVIGI Therapeutics is building
AVIGI is developing VL166 to inhibit heparanase, an enzyme that breaks down protective material around cells.
The kidney programme targets damage to the filtering barrier, which contributes to inflammation and scarring in diabetic and rare kidney diseases.
Developing surgical devices to prevent and treat painful neuromas.
- Country
- Netherlands
- Founded
- 2024
- Sector
- Medtech
- Funding stage
- Seed or earlier
- Founders
Why Atraxon Biotech stands out
Atraxon’s founder Nancy Lamerigts helped build EIT, the 3D-printed spinal implant startup acquired by Johnson & Johnson in 2018.
The startup has patented biodegradable Y- and U-cassettes and moved its Y-Cassette into an approved in-vivo validation study.
What Atraxon Biotech is building
Atraxon is developing biodegradable implants that guide regenerating nerve fibres into graft tissue after nerve injury, amputation or surgery.
The product is designed to simplify surgical nerve management and reduce painful neuroma formation that can disrupt rehabilitation.
Building non-contact AI sleep monitoring for premature babies in neonatal care.
- Country
- Netherlands
- Founded
- 2024
- Sector
- Digital health
- Funding stage
- Seed or earlier
- Founders
Why I See U Baby Care stands out
I See U Baby Care secured a Dutch hospital collaboration in October 2025 to advance its neonatal sleep-monitoring system in a clinical setting.
Founder Chanel Sam co-authored preterm sleep-classification research underpinning the technology and the startup won the 2025 Philips Innovation Award Rough Diamond League.
What I See U Baby Care is building
The system uses a camera above the incubator or bed to classify neonatal sleep-wake state without attaching sensors to the baby.
It is designed to help neonatal teams time routine care around sleep while fitting into existing NICU workflows.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Investment perspective
The investment perspective across this Dutch group is workflow clarity. Each startup has a visible point of entry into care: a ward bed, an operating room, a neonatal unit, a nerve-repair procedure or a kidney-disease mechanism. That makes the commercial story easier to test than a broad platform claim.
The diligence question is whether the added tool creates enough clinical or operational value to justify adoption. Products that reduce manual work, improve surgical confidence or support earlier intervention may be attractive, but only if they fit existing routines and can show evidence that matters to the clinician, hospital or partner expected to adopt them.
Methodology
DealBio selected these startups from its database of early-stage health and longevity startups, focusing on Netherlands-based businesses with published DealBio Startup Briefs and clear relevance to clinical care, hospital workflow or specialist treatment. The selection favours underused startups from the current focus pool and related Dutch briefs, rather than forcing a narrow two-startup theme. DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.